[Cardiovascular risks of selective COX-2-inhibitors].
Schrör
K
K
Institut für Pharmakologie und Klinische Pharmakologie, Universitätsklinikum Düsseldorf. kschroer@uni-duesseldorf.de
D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000453:epidemiology; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D006801:Humans; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D012307:Risk Factors
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases